Botox Eases Migraines and Bruxism: Insights from GRASP Study

MigraineMind
Nov 27, 2025
1 min read

Research Summary

The GRASP study, published in Toxins (Basel), explored the effects of OnabotulinumtoxinA (BoNTA) on chronic migraine and bruxism. Involving 58 patients, the study assessed changes after two BoNTA cycles. Results showed a significant drop in bruxism-related pain, with median scores on the PI-NRS scale plummeting from 7 to 3. Masseter hypertrophy rates also decreased notably. The Bruxscreen-Q questionnaire indicated improvements in bruxism symptoms, and 71% of participants responded positively to BoNTA. The study found a strong correlation between reduced migraine frequency and bruxism pain alleviation, highlighting BoNTA's dual benefits in managing both conditions.

Study Details

📄 Title: OnabotulinumtoxinA to Prevent Chronic Migraine with Comorbid Bruxism: Real-World Data from the GRASP Study Group.

👥 Research Team: Argyriou AA et al.

📚 Published In: Toxins (Basel)

📅 Publication Date: 2025 Nov 3

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.